Live Analyst Rating Changes 54325 upgrades, downgrades & price-target moves Β· freshest Wall Street data, updated daily View live feed β†’
Analyst Tracker/Richard Law CFA
GS

Richard Law CFA

Wall Street Analyst
β˜…β˜…β˜†β˜†β˜†
#2459
on 13Foresight Β· ranked by our own returns
45%
Success Rate
-10.8%
Average Return
21 of 47 calls profitable Β· -21.1% vs benchmark
S&P 500 (SPY)
πŸ“ˆ Across the calls we could measure, roughly 45% of Richard Law CFA's ratings turned a profit when each position was held for 2 year β€” averaging -10.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

29 Buy 21 Hold 8 Sell
Richard's Stock Coverage 22 ratings Β· 2026-11-17
Company Date Position Consensus β“˜ Price Target β“˜ 2-Yr Return vs S&P 500 β“˜
BCAX
Bicara Therapeutics Inc.
Oct 29, 2026 SELL Strong Buy
+247.0% avg upside
16 analysts
$8.00
12.44% Downside
+1.3% Β·
VKTX
Viking Therapeutics
Oct 28, 2026 HOLD Strong Buy
+172.0% avg upside
31 analysts
$34.00
24.57% Upside
+6.0% Β·
RCUS
Arcus Biosciences
Oct 19, 2026 BUY Strong Buy
+98.9% avg upside
22 analysts
$42.00
130.91% Upside
-26.0% Β·
RCKT
Rocket Pharmaceuticals
Oct 08, 2026 HOLD Buy
+546.5% avg upside
30 analysts
$4.00
64.03% Upside
-19.8% Β·
CLDX
Celldex
Oct 05, 2026 HOLD Strong Buy
+43.0% avg upside
28 analysts
$28.00
6.92% Downside
-14.0% Β·
OLMA
Olema Pharmaceuticals
Sep 14, 2026 BUY Strong Buy
+401.3% avg upside
16 analysts
$18.00
157.12% Upside
-29.8% Β·
PTGX
Protagonist Therapeutics
Aug 31, 2026 BUY Strong Buy
-17.0% avg upside
19 analysts
$186.00
28.46% Upside
-15.6% Β·
VRDN
Viridian Therapeutics
Aug 19, 2026 BUY Strong Buy
+42.6% avg upside
32 analysts
$40.00
62.06% Upside
+21.2% Β·
MLYS
Mineralys Therapeutics, Inc.
Aug 12, 2026 BUY Strong Buy
+150.8% avg upside
12 analysts
$40.00
120.01% Upside
-46.5% Β·
SLN
Silence Therapeutics
Jul 27, 2026 SELL Buy
+22.8% avg upside
11 analysts
$4.00
79.83% Downside
-64.0% Β·
COAG
Hemab Therapeutics Holdings, Inc.
Jul 13, 2026 BUY Strong Buy
+29.9% avg upside
6 analysts
$46.00
11.02% Upside
-1.1% Β·
MLTX
MoonLake Immunotherapeutics
May 11, 2026 SELL Strong Buy
+158.9% avg upside
20 analysts
$12.00
1.83% Upside
+40.3% Β·
ARQT
Arcutis Biotherapeutics
Feb 27, 2026 HOLD Strong Buy
+29.0% avg upside
15 analysts
$33.00
2.81% Upside
+1.3% Β·
QTTB
Q32 Bio
Aug 15, 2023 HOLD Strong Buy
+523.8% avg upside
28 analysts
$30.60
243.43% Upside
-90.9% Β·
BEAM
Beam Therapeutics
Aug 09, 2023 HOLD Strong Buy
+91.2% avg upside
25 analysts
$47.00
72.61% Upside
-32.5% Β·
CRSP
Crispr Therapeutics AG
Aug 08, 2023 HOLD Buy
+45.6% avg upside
41 analysts
$63.00
22.42% Upside
+3.7% Β·
KYMR
Kymera Therapeutics
Aug 04, 2023 HOLD Strong Buy
-9.6% avg upside
39 analysts
$37.00
70.72% Downside
+93.4% Β·
NTLA
Intellia Therapeutics
Jun 13, 2023 BUY Buy
+187.2% avg upside
39 analysts
$76.00
509.48% Upside
-82.0% Β·
GLUE
Monte Rosa Therapeutics
May 12, 2023 HOLD Strong Buy
+108.4% avg upside
16 analysts
$11.00
2.25% Upside
-24.8% Β·
EDIT
Editas Medicine
May 05, 2023 HOLD Buy
+398.6% avg upside
33 analysts
$14.00
424.44% Upside
-84.2% Β·
ARVN
Arvinas Holding Company
May 05, 2023 BUY Buy
+257.9% avg upside
28 analysts
$61.00
676.15% Upside
-69.8% Β·
CCCC
C4 Therapeutics
Feb 24, 2023 HOLD Strong Buy
+405.9% avg upside
21 analysts
$10.00
196.79% Upside
-45.8% Β·
πŸ”’ 17 more ratings β€” with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Richard Law CFA β€” Frequently Asked Questions
How accurate are Richard Law CFA's stock ratings?
Based on the calls 13Foresight could measure, about 49% of Richard's ratings were profitable over a one-year hold, with an average return of -1.1% per rating, or -7.4% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Richard ranked on 13Foresight?
Richard Law CFA is currently ranked #2459 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge β€” so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Richard cover?
Richard most recently has ratings on BCAX, VKTX, RCUS, RCKT, CLDX, OLMA, PTGX, VRDN, MLYS, SLN, COAG, MLTX and 10 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.